Lisdexamfetamine Dimesylate: A New Therapeutic Option for Attention-Deficit Hyperactivity Disorder
Abstract
Attention-deficit hyperactivity disorder (ADHD) is associated with substantial functional, clinical and economic burdens. It is among the most common psychiatric disorders in children and adolescents, and often persists into adulthood. Both medication and psychosocial interventions are recommended for the treatment of ADHD. However, ADHD treatment practices vary considerably, depending on medication availability, reimbursement and the evolution of clinical practice in each country. In Europe, stimulants and atomoxetine are widely available medications for the treatment of ADHD, whereas in the US approved treatment options also include extended-release formulations of clonidine and guanfacine. Lisdexamfetamine dimesylate (lisdexamfetamine) is a long-acting, prodrug formulation of dexamfetamine. It is currently licensed in the US, Canada and Brazil, and is undergoing phase III studies in Europe. We performed a PubMed/MEDLINE search looking for recent (2005-2012) scientific papers regarding the pharmacokinetics, pharmacodynamics, efficacy and safety of lisdexamfetamine. The lisdexamfetamine molecule is therapeutically inactive and is enzymatically hydrolysed, primarily in the blood, to the active dexamfetamine. This conversion is unaffected by gastrointestinal pH and variations in normal transit times. Lisdexamfetamine was developed with the goal of providing an extended duration of effect that is consistent throughout the day. Clinical trials have demonstrated robust clinical efficacy of lisdexamfetamine in the treatment of children, adolescents and adults with ADHD with dose-dependent improvements in the core symptoms of ADHD. Studies have further shown that the duration of action of lisdexamfetamine continues for 13 hours post-dosing in children and for 14 hours in adults. The tolerability profile of lisdexamfetamine is consistent with those of other stimulant medications, with decreased appetite, insomnia, abdominal pain and irritability among the more frequent treatment-emergent adverse events, most of which are mild to moderate in intensity and transient in nature. There are currently no parallel-group, head-to-head trial data comparing the efficacy and safety of lisdexamfetamine with other medications for ADHD. However, the available data, including a large effect size and consistent plasma concentrations throughout the day, suggest that lisdexamfetamine is a useful treatment option for patients with ADHD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
LDX is the only stimulant prodrug.
“LDX is the only stimulant prodrug.”
From Associations of sleep disturbance with ADHD: implications for treatment (2015) · cites this paper as Steer et al. 2012
After oral administration, rate-limiting enzymatic hydrolysis of LDX in the bloodstream releases the pharmacologically active d-amfetamine moiety from the lysine conjugate.
“After oral administration, rate-limiting enzymatic hydrolysis of LDX in the bloodstream releases the pharmacologically active d-amfetamine moiety from the lysine conjugate (Steer et al. 2012).”
From Associations of sleep disturbance with ADHD: implications for treatment (2015) · cites this paper as Steer et al. 2012
Cites
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771 · see citing works
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346 · see citing works
FARAONE, S. V., BIEDERMAN, J., & MICK, E. (2006) · Psychological Medicine · doi:10.1017/s003329170500471x · Cited by 2,267 · see citing works
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185 · see citing works
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765 · see citing works
Molina, B. S. G., Hinshaw, S. P., Swanson, J. M., Arnold, L. E., Vitiello, B., Jensen, P. S., Epstein, J. N., Hoza, B., Hechtman, L., Abikoff, H. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31819c23d0 · Cited by 1,182 · see citing works
Size of Treatment Effects and Their Importance to Clinical Research and Practice
KRAEMER, H. C., & Kupfer, D. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.014 · Cited by 850 · see citing works
European clinical guidelines for hyperkinetic disorder ? first upgrade
Taylor, E., D�pfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1002-x · Cited by 682 · see citing works
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677 · see citing works
The quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516 · see citing works
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · cited 2× · see citing works
“02).([50]) The number needed to treat (NNT) was lower for amfetamines (2.”
BackgroundPLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442 · see citing works
DIAMOND, A. (2005) · Development and Psychopathology · doi:10.1017/s0954579405050388 · Cited by 428 · see citing works
Increased Methylphenidate Usage for Attention Deficit Disorder in the 1990s
Safer, D. J., ZITO, J. M., & Fine, E. M. (1996) · PEDIATRICS · doi:10.1542/peds.98.6.1084 · Cited by 410 · see citing works
Biederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80083-x · Cited by 404 · see citing works
Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., Danckaerts, M., Döpfner, M., Faraone, S. V., Rothenberger, A., et al. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-0549-0 · Cited by 375 · see citing works
Biederman, J., Boellner, S. W., Childress, A., Lopez, F. A., Krishnan, S., & Zhang, Y. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.015 · Cited by 356 · see citing works
Estimating the size of treatment effects: moving beyond p values.
McGough, J. J., & Faraone, S. V. (2009) · PubMed Central · Cited by 274 · see citing works
Anti-hyperactivity medication: methylphenidate and amphetamine
Seeman, P., & Madras, B. K. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000421 · Cited by 252 · see citing works
Recent Trends in Stimulant Medication Use Among U.S. Children
Zuvekas, S. H., Vitiello, B., & Norquist, G. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.4.579 · Cited by 228 · see citing works
Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0903 · Cited by 218 · see citing works
Escobar, R., Soutullo, C. A., Amaia Hervas, G., Gastaminza, X., Polavieja, P., & Gilaberte, I. (2005) · PEDIATRICS · doi:10.1542/peds.2005-0386 · Cited by 189 · see citing works
Self-citationArria, A. M., Caldeira, K. M., O’Grady, K. E., Vincent, K. B., Johnson, E. P., & Wish, E. D. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.2.156 · Cited by 182 · see citing works
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170 · cited 1× · see citing works
“Following oral administration and absorption into the circulation, the covalent amide linkage between dexamfetamine and l-lysine is enzymatically hydrolysed in the blood, releasing the active agent.([16]) Since the parent drug does not bind to sites responsible for noradrenaline and dopamine reuptake, the drug require…”
BackgroundAdvokat, C. D., Guidry, D., & Martino, L. (2008) · Journal of American College Health · doi:10.3200/jach.56.6.601-606 · Cited by 170 · see citing works
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149 · see citing works
Coghill, D., Soutullo, C. A., d'Aubuisson, C., Preuss, U., Lindback, T., Silverberg, M., & Buitelaar, J. K. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-31 · Cited by 147 · see citing works
Self-citationThe nonmedical use of prescription ADHD medications: results from a national Internet panel
Novak, S. P., Kroutil, L. A., Williams, R. L., & Brunt, D. L. V. (2007) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/1747-597x-2-32 · Cited by 142 · see citing works
Pelham, W. E., Gnagy, E. M., Chronis, A. M., Burrows-MacLean, L., Fabiano, G. A., Onyango, A. N., Meichenbaum, D. L., Williams, A., Aronoff, H. R., & Steiner, R. L. (1999) · PEDIATRICS · doi:10.1542/peds.104.6.1300 · Cited by 138 · see citing works
Is Attention Deficit Hyperactivity Disorder Increasing Among Girls in the US?
Robison, L. M., Skaer, T. L., Sclar, D. A., & Galin, R. S. (2002) · CNS Drugs · doi:10.2165/00023210-200216020-00005 · Cited by 136 · see citing works
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-34 · Cited by 136 · cited 1× · see citing works
“001).([46]) Furthermore, medium-to-large effect sizes based on PERMP scales were maintained until 14 hours post-dose.”
BackgroundWinterstein, A. G., Gerhard, T., Shuster, J. J., ZITO, J. M., Johnson, M. R., Liu, H., & Saidi, A. S. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k143 · Cited by 132 · see citing works
Self-citationEvolution of the treatment of attention-deficit/hyperactivity disorder in children: A review
Findling, R. L. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.006 · Cited by 129 · see citing works
Findling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.01.007 · Cited by 120 · see citing works
the 311 Study Group, Wigal, S. B., Kollins, S. H., Childress, A. C., & Squires, L. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-17 · Cited by 112 · see citing works
Faraone, S. V., & Upadhyaya, H. P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.1107e28 · Cited by 110 · see citing works
Use of ADHD drugs in the Nordic countries: a population-based comparison study
Zoëga, H., Furu, K., Halldórsson, M., Thomsen, P. H., Sourander, A., & Martikainen, J. E. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01607.x · Cited by 107 · see citing works
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093841 · Cited by 100 · see citing works
Weisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900024056 · Cited by 94 · see citing works
Findling, R. L., Childress, A. C., Krishnan, S., & McGough, J. J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016898 · Cited by 90 · see citing works
Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate
Krishnan, S. M., Pennick, M., & Stark, J. G. (2008) · Clinical Drug Investigation · doi:10.2165/0044011-200828120-00002 · Cited by 85 · see citing works
Schübert, I., Köster, I., & Lehmkuhl, G. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0615 · Cited by 79 · see citing works
Krishnan, S., & Zhang, Y. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007310381 · Cited by 73 · see citing works
Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009357346 · Cited by 72 · see citing works
Boellner, S. W., Stark, J. G., Krishnan, S., & Zhang, Y. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.02.011 · Cited by 72 · see citing works
New Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder
Connor, D. F., & Steingard, R. J. (2004) · CNS Drugs · doi:10.2165/00023210-200418140-00005 · Cited by 71 · see citing works
Prevalence and patterns of methylphenidate use in French children and adolescents
Knellwolf, A., Deligne, J., Chiarotti, F., Auleley, G.-R., Palmieri, S., Blum‐Boisgard, C., Panei, P., & Autret‐Leca, E. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0401-6 · Cited by 65 · see citing works
Attention-Deficit Hyperactivity Disorder
MAY, D. E., & Kratochvil, C. J. (2009) · Drugs · doi:10.2165/11530540-000000000-00000 · Cited by 62 · see citing works
Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers
Krishnan, S. M., & Stark, J. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x242737 · Cited by 55 · cited 2× · see citing works
“Furthermore, based on trough plasma concentrations, dexamfetamine steady state is achieved after approximately five daily doses of lisdexamfetamine, and there is no unexpected accumulation of the parent compound or dexamfetamine.([20]) From a clinical perspective, the pharmacokinetic profile of dexamfetamine following…”
BackgroundPreuss, U., Ralston, S. J., Baldursson, G., Falissard, B., Lorenzo, M. J., Pereira, R. R., Vlasveld, L., Coghill, D., & ADORE Study Group* (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-006-1002-0 · Cited by 54 · see citing works
Krishnan, S., & Moncrief, S. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011973 · Cited by 50 · see citing works
Findling, R. L., Ginsberg, L. D., Jain, R., & Gao, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0165 · Cited by 45 · see citing works
Surman, C. B. H., & Roth, T. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m06838 · Cited by 42 · see citing works
Adler, L. A., Weisler, R. H., Goodman, D. W., Hamdani, M., & Niebler, G. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05335pur · Cited by 42 · cited 1× · see citing works
“The initial dosage for lisdexamfetamine is 30mg once daily, taken in the morning up to a maximum of 70mg/day.([62]) Lisdexamfetamine is usually titrated slowly, increasing the dose every 4–7 days (in 20mg increments) until a therapeutic dose is reached.”
BackgroundIncidence and prevalence of drug-treated attention deficit disorder among boys in the UK.
Jick, H., Kaye, J. A., & Black, C. (2004) · Europe PMC (PubMed Central) · Cited by 40 · see citing works
Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth
Faraone, S. V., Spencer, T. J., Kollins, S. H., & Glatt, S. J. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-201001000-00006 · Cited by 39 · see citing works
Effect of Lisdexamfetamine Dimesylate on Sleep in Children With ADHD
Giblin, J. M., & Strobel, A. L. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710371195 · Cited by 38 · see citing works
Adler, L. A., Goodman, D., Weisler, R. H., Hamdani, M., & Roth, T. G. (2009) · Behavioral and Brain Functions · doi:10.1186/1744-9081-5-34 · Cited by 36 · see citing works
Haffey, M. B., Buckwalter, M., Zhang, P., Homolka, R., Martin, P., Lasseter, K. C., & Ermer, J. C. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2048 · Cited by 34 · see citing works
Prevalence of Methylphenidate Use among Israeli Children
Vinker, S., Vinker, R., & Elhayany, A. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626030-00006 · Cited by 32 · see citing works
Gumy, C., Huissoud, T., & Dubois-Arber, F. (2010) · Journal of Attention Disorders · doi:10.1177/1087054709356386 · Cited by 30 · see citing works
Brown, T. E., Brams, M., Gao, J., Gasior, M., & Childress, A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2196 · Cited by 29 · see citing works
Jain, R., Babcock, T., Burtea, T., Dirks, B., Adeyi, B., Scheckner, B., & Lasser, R. (2011) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-5-35 · Cited by 26 · see citing works
Brams, M. N., Mao, A. R., & Doyle, R. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.09.1909 · Cited by 25 · see citing works
Prevalence of and Change in the Prescription of Methylphenidate in Israel Over a 2-Year Period
Fogelman, Y., Vinker, S., Guy, N., & Kahan, E. (2003) · CNS Drugs · doi:10.2165/00023210-200317120-00005 · Cited by 24 · see citing works
Use of Medical Services by Methylphenidate-Treated Children in the General Population
Miller, A. R., Brehaut, J., Raina, P. S., McGrail, K. M., & Armstrong, R. W. (2004) · Ambulatory Pediatrics · doi:10.1367/a03-031r1.1 · Cited by 21 · see citing works
Effect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder
Wigal, T., Brams, M., Gasior, M., Gao, J., & Giblin, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.03.2275 · Cited by 17 · see citing works
Donker, G., Groenhof, F., & van der Veen, W. J. (2005) · PubMed · Cited by 16 · see citing works
Diagnóstico y tratamiento farmacológico del trastorno por déficit de atención e hiperactividad
Soutullo, C. A. (2003) · Medicina Clínica · doi:10.1016/s0025-7753(03)73657-4 · Cited by 15 · see citing works
Self-citationFogelman, Y., & Kahan, E. (2001) · PubMed · Cited by 13 · see citing works
Correlates of Methylphenidate Use in Canadian Children: A Cross-Sectional Study
Charach, A., Cao, H., Schachar, R. J., & To, T. M. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100105 · Cited by 13 · see citing works
Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes.
Manos, M. J. (2008) · PubMed Central · Cited by 11 · see citing works
Lisdexamfetamine dimesylate for childhood ADHD
Madaan, V. (2008) · Drugs of Today · doi:10.1358/dot.2008.44.5.1215724 · Cited by 11 · see citing works
Findling, R. L., Adeyi, B. A., Chen, G., Dirks, B., Babcock, T., Scheckner, B., Lasser, R. A., Pucci, M. L., Abdullah, H. I., & McGough, J. J. (2010) · CNS Spectrums · doi:10.1017/s1092852900000535 · Cited by 10 · see citing works
Jain, R., Babcock, T., Burtea, T., Dirks, B., Adeyi, B., Scheckner, B., Lasser, R., Renna, J., & Duncan, D. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0027-2 · Cited by 9 · see citing works
Romano, E., Thornhill, S., & Lacourse, É. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.05.028 · Cited by 8 · see citing works
Diagnóstico y tratamiento farmacológico del trastorno por déficit de atención e hiperactividad
Soutullo, C. A. (2003) · Medicina Clínica · doi:10.1157/13043316 · Cited by 3 · see citing works
Self-citation
Flagged first, then by citations
1 of the 78 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Associations of sleep disturbance with ADHD: implications for treatment
Hvolby, A. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0151-0 · Cited by 339 · see citing works
Dolder, P. C., Strajhar, P., Vizeli, P., Hammann, F., Odermatt, A., & Liechti, M. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00617 · Cited by 57 · see citing works
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine
Guerdjikova, A. I., Mori, N., Casuto, L. S., & McElroy, S. L. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s80881 · Cited by 40 · see citing works
Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers
Kaland, M. E., & Klein‐Schwartz, W. (2015) · Clinical Toxicology · doi:10.3109/15563650.2015.1027903 · Cited by 39 · see citing works
Drug-induced endocrine blood pressure elevation
Beck, K. R., Thompson, G. R., & Odermatt, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104311 · Cited by 36 · see citing works
Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD
Frampton, J. E. (2018) · Drugs · doi:10.1007/s40265-018-0936-0 · Cited by 34 · see citing works
Lisdexamfetamine: A pharmacokinetic review
Comiran, E., Kessler, F. H., Fröehlich, P. E., & Limberger, R. P. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.026 · Cited by 31 · see citing works
Lisdexamfetamine: A Review in ADHD in Adults
Frampton, J. E. (2016) · CNS Drugs · doi:10.1007/s40263-016-0327-6 · Cited by 37 · see citing works
Successes, failures, and future prospects of prodrugs and their clinical impact
Najjar, A., & Karaman, R. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1567487 · Cited by 28 · see citing works
Murkett, K., Sharman, J., & Pennick, M. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s70382 · Cited by 27 · see citing works
Strajhar, P., Vizeli, P., Patt, M., Dolder, P. C., Kratschmar, D. V., Liechti, M. E., & Odermatt, A. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.10.016 · Cited by 17 · see citing works
Najib, J. S., Didenko, E., Meleshkina, D., Yusupov, K., Maw, K., Ramnarain, J., & Tabassum, M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1815002 · Cited by 12 · see citing works
Czoty, P. W., Tran, P. V., Thomas, L. N., Martin, T. J., Grigg, A., Blough, B. E., & Beveridge, T. J. R. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3875-4 · Cited by 10 · see citing works
Ichikawa, H., Miyajima, T., Yamashita, Y., Fujiwara, M., Fukushi, A., & Saito, K. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0076 · Cited by 10 · see citing works
Ichikawa, H., Miyajima, T., Yamashita, Y., Fujiwara, M., Fukushi, A., & Saito, K. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12091 · Cited by 10 · see citing works
Thevis, M., Sigmund, G., Thomas, A., Vogel, M., Walpurgis, K., Kwiatkowska, D., Geyer, H., & Schänzer, W. (2014) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6844 · Cited by 7 · see citing works
The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders
Roncero, C., & Alvarez, E. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.932691 · Cited by 7 · see citing works
Daghmoum, M., Sabat, N., Lecoq, M., Viraize, T., & Guinchard, X. (2025) · ACS Catalysis · doi:10.1021/acscatal.4c07259 · Cited by 6 · see citing works
Walitza, S., Romanos, M., Warnke, A., Greenhill, L. L., & Gerlach, M. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_8 · Cited by 6 · see citing works
Dopantes cerebrales en el tratamiento del TDAH
Pallardo-Fernández, I. (2015) · Psiquiatría Biológica · doi:10.1016/j.psiq.2015.10.004 · Cited by 5 · see citing works
Walitza, S., Gerlach, M., Romanos, M., & Renner, T. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_8 · Cited by 5 · see citing works
Binge eating disorder hidden behind a wall of anxiety disorders
Pipe, A., Patterson, B. A., & Ameringen, M. V. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200235 · Cited by 4 · see citing works
Rising prescription stimulant poisoning in Australia: a retrospective case series
Martin, C., Harris, K., Wylie, C., & Isoardi, K. (2023) · Toxicology Communications · doi:10.1080/24734306.2023.2174689 · Cited by 4 · see citing works
Binge eating disorder hidden behind a wall of anxiety disorders
Pipe, A., Patterson, B. A., & Ameringen, M. V. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn200235 · Cited by 2 · see citing works
What place for ▼lisdexamfetamine in children and adolescents with ADHD?
BMJ Publishing Group Ltd (2013) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2013.10.0208 · Cited by 1 · see citing works
Intervention, Treatment, and Management of ADHD
Vloet, T. D., von Polier, G. G., & Herpertz‐Dahlmann, B. (2020) · doi:10.1002/9781119159322.ch33 · Cited by 1 · see citing works
Sánchez, C. R., & Calvo, I. (2021) · Fisioterapia · doi:10.1016/j.ft.2021.04.004
Jesus, R. C. D., Anjos, S. N. S. D., & Neri, F. S. M. (2022) · Revista Contemporânea · doi:10.56083/rcv2n6-026
Walitza, S., Smigielski, L., & Gerlach, M. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_8
Effects of exposure to lisdexamfetamine dimesylate on hepatic parameters of pubertal rats
da Silva, J. V. H., Santos, L. C., Erthal, R. P., dos Santos, D. P., Ferraz, C. R., de Souza, C. F., Gonçalves, L. E. D., Verri, W. A., Jr., Câmara, N. O. S., Uchôa, E. T., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05370-1
- Authors
- Steer, C., Froelich, J., Soutullo, C. A., Johnson, M., & Shaw, M.
- Affiliations
- Victoria Hospital (GB)
- Clinica Universidad de Navarra (ES)
- Drottning Silvias barn- och ungdomssjukhus (SE)
- Corresponding author
- Steer, Christopher
- Venue
- CNS Drugs
- Published
- 2012-08
- Volume
- 26
- Issue
- 8
- Pages
- 691-705
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2075448044
- Semantic Scholar
- bba8f9f4ac9c4b0ecef4b72f79e1ec6985d93593
- Cited by
- 30
- References
- 78
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 1
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, ADHD medication, stimulant medication, pharmacokinetics, pharmacodynamics, drug efficacy, drug safety, adverse events, children and adolescents, adults
- MeSH terms
- Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Dextroamphetamine, Dose-Response Relationship, Drug, Humans, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
